Angitia Biopharmaceuticals

Angitia Biopharmaceuticals is a private, clinical-stage biotech with a focused pipeline of three biologic candidates targeting high-need musculoskeletal conditions, including osteoporosis and osteogenesis imperfecta. The company is led by industry veteran Dr. Hua Zhu (David) Ke, who previously contributed to the development of blockbuster bone drugs like Prolia and Evenity. With a strong financial position bolstered by a recent $130M Series D round in 2026, Angitia is advancing multiple Phase 2 trials globally while building on a foundation of proven scientific acumen in bone biology.

Leverages deep expertise in bone biology and musculoskeletal drug development, built on the founder's proven track record in discovering blockbuster bone therapeutics (e.g., Prolia, Evenity). Focuses on developing novel antibody-based biologics targeting validated pathways in bone formation and repair.

In osteoporosis, Angitia will compete against established giants (Amgen, UCB) with drugs like Prolia and Evenity, as well as newer anabolic agents. In osteogenesis imperfecta, competition includes sclerostin inhibitors and other bone-building therapies in development. The spinal fusion adjuvant market features competition from medical device companies and existing bone graft materials.